New Jersey Assembly Bill A1136

New Jersey 2022-2023 Regular Session

• Introduced: 1/11/22
• Refer: 1/11/22

Caption

Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.

Impact

The bill has implications for both health insurance practices and patient care in the state. Specifically, health insurance policies (both individual and group plans) must cover the costs associated with the DPD deficiency testing annually, as well as any necessary prescription drug treatments related to this condition. This requirement ensures that patients have access to critical tests that can mitigate the risks associated with chemotherapy, aligning New Jersey’s healthcare laws with best practices for patient safety.

Summary

A1136 is a bill introduced in New Jersey that mandates physicians to offer testing for dihydropyrimidine dehydrogenase deficiency (DPD deficiency) to patients before they undergo chemotherapy. DPD deficiency is a significant condition as it can lead to severe adverse reactions from standard chemotherapy drugs if left undiagnosed. The bill aims to improve patient safety by ensuring that this condition is identified upfront, allowing for better management of chemotherapy treatments for affected individuals. Such proactive measures are expected to contribute to more positive treatment outcomes for cancer patients.

Contention

While the bill is largely seen as a beneficial measure for enhancing patient safety, it may encounter some opposition regarding the financial burden placed on healthcare insurers and potential implications for healthcare costs. Critics could argue about the practicality of enforcing such testing across all patients, raising questions about the costs of additional testing versus the benefits of preventing adverse reactions to chemotherapy. Thus, the bill sits at the intersection of patient care improvements and the economic realities of healthcare funding.